Lakefront Biotherapeutics (LKFT) Net Cash Flow (2015 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Net Cash Flow for 12 consecutive years, with -$39.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Cash Flow fell 191.85% year-over-year to -$39.4 million; the TTM figure through Mar 2026 stood at -$46.2 million (down 683.45% YoY), while the FY2025 annual figure was -$26.0 million, up 87.92% from the prior year.
• Net Cash Flow fell to -$39.4 million in Q1 2026 per LKFT's latest filing, from -$4.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $42.9 million in Q1 2025 and bottomed at -$1.1 billion in Q1 2022.
• Historically, Net Cash Flow has averaged -$144.6 million across 5 years, with a median of -$27.5 million in 2023.
• Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 667.17% — and 2025, when it soared 137.14%.
• Lakefront Biotherapeutics' Net Cash Flow stood at -$167.0 million in 2022, then jumped by 83.5% to -$27.5 million in 2023, then dropped by 18.37% to -$32.6 million in 2024, then jumped by 85.68% to -$4.7 million in 2025, then slumped by 743.36% to -$39.4 million in 2026.
• Business Quant data shows LKFT's Net Cash Flow at -$39.4 million in Q1 2026, -$4.7 million in Q4 2025, and -$1.5 million in Q3 2025.